Marisa Wexler, MS,  senior science writer—

Use of Bellerophon Therapeutics’ INOpulse device — which provides nitric oxide to the lungs — significantly improved parameters related to blood flow in the lungs in people with pulmonary hypertension associated with pulmonary fibrosis (PH-PF), top-line data from…

Vitamin C deficiency can cause pulmonary arterial hypertension (PAH), a new case report suggests, highlighting the need to test vitamin C levels in people with PAH. The report, “Vitamin C Deficiency-Induced Pulmonary Arterial Hypertension,” was published in the journal CHEST. The study details the case of…

Treatment with sotatercept (ACE-011) eased heart strain and improved exercise capacity in individuals with pulmonary arterial hypertension (PAH) participating in the Phase 2 PULSAR trial, according to Acceleron Pharma, the therapy’s manufacturer. Sotatercept is an investigational compound designed to bind and entrap proteins…

Levels of a circular RNA molecule in the blood could help diagnose and predict the clinical outcomes of those with idiopathic pulmonary arterial hypertension (IPAH), a study suggests. The study, “Elevated serum circ_0068481 levels as a potential diagnostic and prognostic indicator in idiopathic pulmonary arterial hypertension,”…

Over the last year, Pulmonary Hypertension News has brought you the latest news about groundbreaking discoveries, treatment developments, clinical trials, and other events related to pulmonary hypertension (PH). As we look ahead to 2020, here are our top 10 most-read stories of 2019, with a summary of their significance for…

TriAxia Health is partnering with three academic medical centers to build a large database aiming for a better understanding of rare pulmonary diseases, beginning with pulmonary arterial hypertension (PAH). To be meaningful, medical research often requires very large quantities of data. Bigger datasets give a study greater statistical…

Cardiopulmonary exercise testing can improve the ability of an algorithm to identify systemic sclerosis patients who have pulmonary arterial hypertension (PAH), a new study suggests. The study, “Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis,” was published in…

Having pulmonary hypertension (PH) does not affect the benefits of lung volume reduction surgery for people with emphysema, who experience improved lung function and better quality of life, a new study suggests. The study, published in The Annals of Thoracic Surgery, was titled “Pulmonary Hypertension: A…

INOpulse can improve physical activity in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and helps them to maintain a higher level of activity, data presented at the 2019 meeting of the American College of Chest Physicians suggest. INOpulse is a therapy that uses inhaled nitric oxide (iNO),…

Adcirca (tadalafil) helped to improve survival in dogs with pulmonary hypertension (PH), a new study suggests. Knowing the underlying conditions associated with PH can lead to improved health outcomes in dogs, the study stated. The findings might also prove to be important in understanding the disease in humans.

Altavant Sciences presented its patient-centered approach to drug development, which informed the design of an ongoing Phase 2 study, at the Pulmonary Hypertension Association’s recent Annual PH Professional Network (PHPN) Symposium. The effort was detailed in the poster “A Framework for Engaging PAH Patients in…

A pulmonary hypertension (PH) patient has become the 1,000th recipient of a lung transplant at the University of Washington (UW) Medicine, the hospital recently announced. UW Medicine, the only institution in the Pacific Northwest that offers lung transplants, is the 11th in the United States to hit this…